OncoMatch/Clinical Trials/NCT06225843
Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
Is NCT06225843 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Sotevtamab and FOLFOX for metastatic colorectal cancer.
Treatment: Sotevtamab · FOLFOX — This Phase II study will recruit 17 colorectal cancer patients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks for the first 4 cycles followed by liver metastases resection surgery with or without primary cancer resection. One cycle of treatment will consist of 14 days (2 weeks).
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Excluded: MMR deficient
Participants with MMR-deficient primary colorectal tumor
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: sotevtamab (sotevtamab)
Participants who have received prior therapy with sotevtamab
Cannot have received: chemotherapy for metastatic disease
Exception: Prior adjuvant chemotherapy and radiotherapy following resection of primary tumor is acceptable if completed at least 12 months prior to trial enrolment.
Participants must not have received prior chemotherapy for metastatic disease. Prior adjuvant chemotherapy and radiotherapy following resection of primary tumor is acceptable if completed at least 12 months prior to trial enrolment.
Lab requirements
Blood counts
adequate organ and immune function
Kidney function
adequate organ and immune function
Liver function
adequate organ and immune function
Participants must have adequate organ and immune function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify